Guest Contributor

Sofinov lead investor in new early-stage life science fund following success of T2C2/Bio

Guest Contributor
April 23, 2001

CDF Sofinov has spearheaded the creation of a $94-million venture capital fund devoted to early-stage life science opportunities, following its success with T2C2/Bio which was launched in 1997 with an initial investment of $15 million.

... Please become a Member or login to read the rest of this article ...


Other stories mentioning these organizations, people and topics

Other News

Ecommerce growing but still struggling in infancy

IRAP laying groundwork for increased emphasis on international activity

DFAITS’s S&T division seeks to carve out enhanced role with new strategy and increased collaboration with SBDAs

Funding of regional genome centres sets stage for Canada’s return to international genome research






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 0 free articles remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.